BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

Recruiting

Phase 1

BGB-290 & TemozolomideBGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

Sponsor:

UCLA

Code:

NCT03749187

Conditions

Glioblastoma

IDH1 Gene Mutation

IDH2 Gene Mutation

Low Grade Glioma

Malignant Glioma

Eligibility Criteria

Sex: All

Age: 13 - 39

Healthy Volunteers: Not accepted

Interventions

PARP Inhibitor BGB-290

Temozolomide (TMZ)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-06. This information was provided to ClinicalTrials.gov by University of California, San Francisco on 2025-08-01.